{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:53:43Z","timestamp":1760151223409,"version":"build-2065373602"},"reference-count":54,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T00:00:00Z","timestamp":1644710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["10077260"],"award-info":[{"award-number":["10077260"]}],"id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Foundation of Korea (NRF)","award":["2020R1A6A1A03040516"],"award-info":[{"award-number":["2020R1A6A1A03040516"]}]},{"name":"Ministry of Science and ICT of Korea","award":["21\u2012DPIC\u201215"],"award-info":[{"award-number":["21\u2012DPIC\u201215"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>This study aimed to observe adverse events following immunisation (AEFIs) that affected recovery within two weeks after COVID-19 vaccination and investigate their risks in propensity-score-matched populations. Data were collected from 447,346 reports from the VAERS between 1 January 2021 and 31 July 2021. Propensity-score-matched populations were constructed by adjusting for demographic characteristics and 11 underlying diseases in eligible subjects who received 1 of 3 COVID-19 vaccines: 19,462 Ad26.COV2.S, 120,580 mRNA-1273, and 100,752 BNT162b2. We observed that 88 suspected AEFIs (22 in Ad26.COV2.S, 62 in mRNA-1273, and 54 in BNT162b2) were associated with an increased risk of delayed recovery within 2 weeks after COVID-19 vaccinations. Nervous system, musculoskeletal and connective tissue, gastrointestinal, skin, and subcutaneous tissue disorders were the most common AEFIs after COVID-19 vaccination. Interestingly, four local and systemic reactions affected recovery in different vaccine recipients during our study period: asthenic conditions and febrile disorders in Ad26.COV2.S and mRNA-1273; general signs and symptoms in mRNA-1273 and BNT162b2; injection site reactions in Ad26.COV2.S and BNT162b2. Although it is necessary to confirm a causal relationship with COVID-19 vaccinations, some symptoms, including paralysis, allergic disorders, breathing abnormalities, and visual impairment, may hinder the recovery of these recipients.<\/jats:p>","DOI":"10.3390\/vaccines10020284","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T20:35:28Z","timestamp":1644784528000},"page":"284","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Propensity-Score-Matched Evaluation of Adverse Events Affecting Recovery after COVID-19 Vaccination: On Adenovirus and mRNA Vaccines"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5682-1770","authenticated-orcid":false,"given":"Chang-Sik","family":"Son","sequence":"first","affiliation":[{"name":"Division of Intelligent Robot, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-6120","authenticated-orcid":false,"given":"Sang-Hyeon","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Intelligent Robot, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1034-454X","authenticated-orcid":false,"given":"Won-Seok","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Intelligent Robot, Daegu Gyeongbuk Institute of Science and Technology (DGIST), Daegu 42988, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"ref_2","first-page":"1","article-title":"Informing selection of drugs for COVID-19 treatment through adverse events analysis","volume":"11","author":"Guo","year":"2021","journal-title":"Sci. Rep."},{"unstructured":"(2021, December 09). FDA Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus. Fact Sheet for Healthcare Providers Administering Vaccine, Available online: https:\/\/www.fda.gov\/media\/144413\/download.","key":"ref_3"},{"unstructured":"(2021, October 26). FDA Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19). Fact Sheet for Healthcare Providers Administering Vaccine, Available online: https:\/\/www.fda.gov\/media\/144637\/download?utm_medium=email&utm_source=govdelivery.","key":"ref_4"},{"unstructured":"(2021, October 26). FDA Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19), Available online: https:\/\/www.fda.gov\/media\/146304\/download.","key":"ref_5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"unstructured":"(2021, October 26). FDA Brifing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19, Available online: https:\/\/www.fda.gov\/media\/146217\/download.","key":"ref_8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the advisory committee on immunization practices\u2014United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): Update from the advisory committee on immunization practices\u2014United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jop.13165","article-title":"Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns","volume":"50","author":"Cirillo","year":"2021","journal-title":"J. Oral Pathol. Med."},{"unstructured":"(2021, October 26). FDA Briefing Document Vaccines and Related Biological Products Advisory Committee Meeting, Available online: https:\/\/www.fda.gov\/media\/144434\/download.","key":"ref_14"},{"key":"ref_15","first-page":"1843","article-title":"COVID-19 mRNA vaccines are generally safe in the short term: A vaccine vigilance real-world study says","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"unstructured":"(2021, October 27). Centers for Disease Control and Prevention Vaccine Safety Datalink, Available online: https:\/\/www.cdc.gov\/vaccinesafety\/ensuringsafety\/monitoring\/vsd\/index.html.","key":"ref_16"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the vaccine adverse event reporting system","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"700014","DOI":"10.3389\/fmed.2021.700014","article-title":"Age and gender disparities in adverse events following COVID-19 vaccination: Real-world evidence based on big data for risk management","volume":"8","author":"Xiong","year":"2021","journal-title":"Front. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"670370","DOI":"10.3389\/fmed.2021.670370","article-title":"Mortality rate and characteristics of deaths following COVID-19 vaccination","volume":"8","author":"Lv","year":"2021","journal-title":"Front. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.15585\/mmwr.mm7010e4","article-title":"Body mass index and risk for COVID-19\u2013related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death\u2014united states, march\u2013december 2020","volume":"70","author":"Kompaniyets","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/cid\/ciaa415","article-title":"Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission","volume":"71","author":"Lighter","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.7326\/M20-3742","article-title":"Obesity and mortality among patients diagnosed with COVID-19: Results from an integrated health care organization","volume":"173","author":"Tartof","year":"2020","journal-title":"Ann. Intern. Med."},{"unstructured":"(2021, September 08). CDC Science Brief: Evidence Used to Update the List of Underlying Medical Conditions That Increase a Person\u2019s Risk of Severe Illness from COVID-19, Available online: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34009770.","key":"ref_25"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2215\/CJN.09610620","article-title":"Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19","volume":"16","author":"Bowe","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.ekir.2020.06.013","article-title":"Outcomes for patients with COVID-19 and acute kidney injury: A systematic review and meta-analysis","volume":"5","author":"Qian","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.kint.2020.03.005","article-title":"Kidney disease is associated with in-hospital death of patients with COVID-19","volume":"97","author":"Cheng","year":"2020","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov."},{"doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team (2021). Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 14\u201323, 2020. Morb. Mortal. Wkly. Rep., 70, 46\u201351.","key":"ref_30","DOI":"10.15585\/mmwr.mm7002e1"},{"doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team (2021). Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine\u2014United States, December 21, 2020\u2013January 10, 2021. Morb. Mortal. Wkly. Rep., 70, 125\u2013129.","key":"ref_31","DOI":"10.15585\/mmwr.mm7004e1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"unstructured":"(2021, September 02). MedDRA What\u2019s New MedDRA Version 24.0. Available online: https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/whatsnew_24_0_English.pdf.","key":"ref_33"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00124363-200418050-00001","article-title":"Medical dictionary for regulatory activities (MedDRA)","volume":"18","author":"Fescharek","year":"2004","journal-title":"Int. J. Pharm. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc2010418","article-title":"Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy","volume":"383","author":"Baldi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.jacc.2020.09.549","article-title":"Prognostic impact of prior heart failure in patients hospitalized with COVID-19","volume":"76","author":"Lee","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jchf.2020.05.006","article-title":"Considerations for heart failure care during the COVID-19 pandemic","volume":"8","author":"DeFilippis","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCULATIONAHA.120.047430","article-title":"Pulmonary embolism in patients with COVID-19","volume":"142","author":"Poissy","year":"2020","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1868","DOI":"10.1212\/WNL.0000000000010112","article-title":"Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study","volume":"95","author":"Kremer","year":"2020","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anai.2020.10.002","article-title":"Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019","volume":"126","author":"Rosenthal","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","article-title":"A solution to the problem of monotone likelihood in Cox regression","volume":"57","author":"Heinze","year":"2001","journal-title":"Biometrics"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity following receipt of mRNA-based COVID-19 vaccines","volume":"325","author":"Gee","year":"2021","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First month of COVID-19 vaccine safety monitoring\u2014United States, December 14, 2020\u2013January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: Summary report\u2014Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N. Engl. J. Med."},{"doi-asserted-by":"crossref","unstructured":"Gessler, F., Schmitz, A.K., Dubinski, D., Bernstock, J.D., Lehmann, F., Won, S.-Y., Wittstock, M., G\u00fcresir, E., Hadjiathanasiou, A., and Zimmermann, J. (2021). Neurosurgical considerations regarding decompressive craniectomy for intracerebral hemorrhage after SARS-CoV-2-vaccination in vaccine induced thrombotic thrombocytopenia\u2014VITT. J. Clin. Med., 10.","key":"ref_51","DOI":"10.3390\/jcm10132777"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"unstructured":"(2021, October 18). European Medicines Agency AstraZeneca\u2019s COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Blood Platelets. Available online: https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.","key":"ref_53"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/284\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:18:50Z","timestamp":1760134730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,13]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["vaccines10020284"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10020284","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,2,13]]}}}